Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review

QR Code

Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review

The safety of COVID-19 pharmacotherapy is a relevant issue, first of all, because of the current lack of experience with using particular medicinal products and with off-label prescribing. The aim of the study was to analyse information on potential adverse drug reactions (ADRs) and their predictors...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. V. Kryukov, A. S. Zhiryakova, Yu. V. Shevchuk, A. V. Matveev, V. I. Vechorko, O. V. Averkov, S. V. Glagolev, I. I. Temirbulatov, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, D. A. Sychev
Format:	Article
Language:	Russian
Published:	Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2022-12-01
Series:	Безопасность и риск фармакотерапии
Subjects:	covid-19 adverse drug reactions pharmacovigilance drug-drug interactions pharmacogenetics nirmatrelvir+ritonavir interleukin inhibitors monoclonal antibodies
Online Access:	https://www.risksafety.ru/jour/article/view/340
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bioequivalence study of generic nirmatrelvir in healthy volunteers
by: R. A. Oseshnyuk, et al.
Published: (2023-05-01)

What’s new in the etiotropic therapy of coronavirus infection?
by: A. V. Budnevsky
Published: (2022-10-01)

Safety of Therapy with Tocilizumab and Other Interleukin Inhibitors
by: V. I. Petrov, et al.
Published: (2022-04-01)

Predicting the risk of developing drug-induced liver injury during remdesivir therapy in COVID-19 patients using machine learning
by: Yu. V. Shevchuk, et al.
Published: (2024-12-01)

MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION
by: L. A. Balykova, et al.
Published: (2022-10-01)

Pharmacogenetic aspects of the efficacy of nonsteroidal anti-inflammatory drugs and opioid analgesics for postoperative pain relief after total joint arthroplasty
by: A. S. Zhiryakova, et al.
Published: (2025-06-01)

Efficacy of Nirmatrelvir tablet/Ritonavir tablet in patients infected with COVID-19 aged 90 years and older
by: WEI Xueman, et al.
Published: (2025-05-01)

CURRENT ASPECTS OF ETIOTROPIC COVID-19 THERAPY
by: D. N. Zemskov, et al.
Published: (2022-12-01)

Real-world effectiveness and economic analysis of nirmatrelvir/ritonavir, remdesivir, and molnupiravir for treatment of COVID-19 among ambulatory patients in Thailand
by: Sirapat Korwiwattanakan, et al.
Published: (2025-08-01)

Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: “Symptom Rebound”
by: Ashish Bhargava, et al.
Published: (2025-05-01)

Review of the monograph by Kolbin A. S., Zyryanov S. K., Belousov D. Yu. "Pharmacovigilance" 2025
by: V. I. Petrov
Published: (2025-01-01)

Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS
by: T. N. Komarov, et al.
Published: (2023-05-01)

Aspects of the safe use of medicinal products based on medicinal plant materials in COVID-19
by: A. A. Taube
Published: (2022-01-01)

Evaluating the introduction of COVID-19 oral antivirals through a test and treat program: outcomes from a cohort study in four African countries
by: Jessica T. Joseph, et al.
Published: (2025-09-01)

Genetic features of a patient may influence the efficacy and safety profile of a medicinal product
by: D. A. Sychev
Published: (2024-07-01)

Problematic aspects of participation of pharmacists in the system of pharmacovigilance in Russia
by: E. N. Tkhoseva, et al.
Published: (2022-06-01)

Expert Evaluation of Pharmacovigilance System Documents Included in the Registration Dossier
by: I. I. Snegireva, et al.
Published: (2020-12-01)

Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19?
by: article Editorial
Published: (2022-12-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2023-01-01)

Improving the Pharmacovigilance System in Medical Organisations as an Opportunity to Enhance the Quality of Pharmacotherapy
by: M. V. Zhuravleva, et al.
Published: (2025-04-01)

IS THE PATIENT PARTNERSHIP INFORMATIVE IN PHARMACOVIGILANCE?
by: Yu. V. Muravyev
Published: (2017-09-01)

Monitoring post-approval drug safety in pregnancy: pharmacogenetic aspects
Published: (2018-02-01)

ON THE ISSUE OF SAFETY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
by: N. Yu. Velts, et al.
Published: (2018-09-01)

Patients’ Pharmacogenetic Characteristics and the Risk of Adverse Reactions to Non-steroidal Anti-inflammatory Drugs: Case Reports
by: A. S. Zhiryakova, et al.
Published: (2024-07-01)

Fluoroquinolone antibiotics: safety of use by the example of ciprofloxacin
by: N. V. Molchan, et al.
Published: (2019-06-01)

What is the role of antineoplastic drug safety in reimbursement decision making?
by: A. S. Kolbin, et al.
Published: (2018-11-01)

Levofloxacin: Analysis of Information on Adverse Reactions from Russian Spontaneous Report Database
by: S. K. Zyryanov, et al.
Published: (2020-05-01)

The pharmacogenetics antiepileptic drugs
by: N. A. Shnayder, et al.
Published: (2008-12-01)

Aspects of the Safe Use of Antibacterial Drugs in Community-Acquired Pneumonia: the Implications of Drug-Drug Interactions
by: A. A. Taube, et al.
Published: (2022-08-01)

EFFICACY AND SAFETY OF ANTIEPILEPTIC DRUGS DURING PREGNANCY: PHARMACOGENETIC ASPECTS
by: E. A. Sоkоvа, et al.
Published: (2018-06-01)

Retrospective Analysis of Spontaneous Reports of Fatal Adverse Reactions Associated with Lidocaine
by: A. V. Matveev, et al.
Published: (2024-04-01)

Cost-effectiveness analysis of nirmatrelvir/ritonavir in adult patients at high risk of progressing to severe COVID-19
by: Carolina Moreno, et al.
Published: (2025-07-01)

COMPARATIVE REVIEW OF METHODOLOGIES FOR ESTIMATING THE COST OF ADVERSE DRUG REACTIONS IN THE RUSSIAN FEDERATION AND BRAZIL
by: G. I. Syraeva, et al.
Published: (2021-03-01)

Signal Management: Updated Requirements of the EAEU Good Pharmacovigilance Practice
by: A. V. Matveev, et al.
Published: (2023-03-01)

Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis
by: L. V. Fedina, et al.
Published: (2023-01-01)

Role of Pharmacovigilance in Drug Safety Monitoring
by: Anju E. Paul, et al.
Published: (2025-07-01)

Review of publications on drug-related problems investigations in osteoporosis patients
by: E. A. Egorova, et al.
Published: (2024-01-01)

OPPORTUNITIES TO OPTIMIZE ANTIEPILEPTIC THERAPY WITH USE OF PHARMACOGENETIC BIOMARKERS
by: T. V. Dokukina, et al.
Published: (2016-05-01)

Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study
by: Yu. V. Shevchuk, et al.
Published: (2023-11-01)

A Model for Predicting the Risk of Developing Drug-Induced Liver Injury During Therapy with Favipiravir
by: Yu. V. Shevchuk, et al.
Published: (2025-02-01)